儿茶酚胺能PET示踪剂在神经母细胞瘤中的循证作用:系统评价及与间碘苄胍显像的头对头比较
该系统评价纳入10项头对头比较[123I]-mIBG与儿茶酚胺能PET示踪剂的研究,共181例患者(范围5-46例)。基于患者分析中10项研究仅2项(均用[18F]DOPA)报告PET方法优越;基于病灶分析中10项研究有7项报告PET检出病灶数显著多于闪烁显像。作者结论认为PET/CT诊断性能优于mIBG闪烁显像,但这种优越性是否影响临床决策仍未知。
要点
- 基于患者分析,10项研究中仅2项(均使用[18F]DOPA)报告PET方法优于[123I]-mIBG闪烁显像。
- 基于病灶分析,10项研究中7项报告PET检出病灶数显著多于闪烁显像。
- 作者认为PET检查因采集更快、镇静需求更少和单日完成检查而看似有临床应用前景。
核心结论
- 使用儿茶酚胺能示踪剂的PET/CT诊断性能优于mIBG闪烁显像。
- 目前仍未知这种优越性能否影响临床决策。
- PET检查因采集更快、镇静需求更少和单日完成检查而看似有临床应用前景。
研究设计与样本
- 系统评价,检索PubMed数据库,纳入10项头对头比较[123I]-mIBG与PET放射性药物的研究。
- 纳入研究包括2项[11C]C-HED、4项[18F]DOPA、1项[124I]mIBG和3项[18F]mFBG研究,共181例患者(范围5-46例)。
- 排除综述文章、临床前研究、小病例系列(<5例受试者)、病例报告及非英文文章。
- 从每项研究提取文献信息、技术参数以及基于患者分析(PBA)和基于病灶分析(LBA)的敏感性。
主要发现
- 基于患者分析,10项研究中2项(均使用[18F]DOPA)报告PET方法优越。
- 基于病灶分析,10项研究中7项报告PET检出病灶数显著多于闪烁显像。
关键数值与推荐
- 基于患者分析,10项研究中2项(均使用[18F]DOPA)报告PET方法优越。
- 基于病灶分析,10项研究中7项报告PET检出病灶数显著多于闪烁显像。
临床怎么用
- 原文未据此给出推荐。
局限性
- 目前仍未知PET/CT的优越性能否影响临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [123I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpretation. Many PET catecholaminergic radiotracers have been proposed as a replacement for [123I]-mIBG, however they have not yet made it into clinical practice. We aimed to review the available literature comparing head-to-head [123I]-mIBG with the most common PET catecholaminergic radiopharmaceuticals. METHODS: We searched the PubMed database for studies performing a head-to-head comparison between [123I]-mIBG and PET radiopharmaceuticals including meta-hydroxyephedrine ([11C]C-HED), 18F-18F-3,4-dihydroxyphenylalanine ([18F]DOPA) [124I]mIBG and Meta-[18F]fluorobenzylguanidine ([18F]mFBG). Review articles, preclinical studies, small case series (< 5 subjects), case reports, and articles not in English were excluded. From each study, the following characteristics were extracted: bibliographic information, technical parameters, and the sensitivity of the procedure according to a patient-based analysis (PBA) and a lesion-based analysis (LBA). RESULTS: Ten studies were selected: two regarding [11C]C-HED, four [18F]DOPA, one [124I]mIBG, and three [18F]mFBG. These studies included 181 patients (range 5-46). For the PBA, the superiority of the PET method was reported in two out of ten studies (both using [18F]DOPA). For LBA, PET detected significantly more lesions than scintigraphy in seven out of ten studies. CONCLUSIONS: PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination.
引用
- Piccardo A, Treglia G, Fiz F, et al. The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy. Eur J Nucl Med Mol Imaging. 2023. PMID: 37962616. doi:10.1007/s00259-023-06486-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。